glucosyltransferase

Glucosyltransferase catalyzes the transfer of nucleotide diphosphate-activated monosaccharide units to acceptor molecules.

T4 Phage β-glucosyltransferase is a DNA-modifying enzyme encoded by T4 phage, which facilitates the transfer of glucose from uridine diphosphate glucose to the 5-hydroxymethylcytosine bases in phage T4 DNA.

Protein O-Glucosyltransferase 1 is a glucosyltransferase that modifies the Notch signaling pathway by attaching glucose to serine residues within Notch.

AMP-Deoxynojirimycin (AMP-DNM) is a potent inhibitor of ceramide glucosyltransferase and GCase 2, as well as GlcCer biosynthesis, and is utilized in the study of Parkinson's disease and diabetes.

G43 is a potent and selective glucosyltransferase inhibitor that inhibits GtfB and GtfC with Kd values of 3.7 μM and 46.9 nM, respectively.G43 exhibits in vitro and in vivo anti-Streptococcus mutans activity and can be used for caries studies.

Miglustat (NB-DNJ) is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

6-Ketolithocholic acid is a secondary bile acid formed by further microbial metabolism of primary bile acids in the gut. It is suitable for studying bile acid metabolism and exhibits inhibitory activity against glucosyltransferases.

C6 L-erythro Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is metabolized by ceramide glucosyltransferase to form C6 L-erythro glucosylceramide. C6 L-erythro Ceramide is cytotoxic to U937 cells (IC50 = 18 μM).

C6 L-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It is cytotoxic to U937 cells in vitro (IC50 = 18 μM), metabolically inactive, and unlike C6 L-erythro ceramide, it cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 L-threo Ceramide enhances IL-4 production induced by phorbol 12-myristate 13-acetate in EL4 T cells at 10 μM.

C6 D-threo Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides., C6 D-threo Ceramide is cytotoxic to U937 cells in vitro (IC50 = 18 μM). It is metabolically inactive and, unlike C6 L-erythro ceramide , C6 D-threo ceramide cannot be converted to C6 glucosylceramide by ceramide glucosyltransferase. C6 D-threo Ceramide promotes survival of isolated rat spinal neurons when used at concentrations up to 2.5 μM but induces cell death at concentrations greater than 5 μM. It enhances IL-4 production induced by phorbol 12-myristate 13-acetate in EL4 T cells when used at a concentration of 10 μM.

D,L-erythro-PDMP, an erythro isomer of PDMP, exhibits growth inhibition on cultured rabbit skin fibroblasts. Additionally, this compound serves as an effective inhibitor of UDP-glucose: ceramide glucosyltransferase.

Ibiglustat (GZ402671) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.

Ibiglustat hydrochloride is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor.

D,L-erythro-PDMP hydrochloride, an erythro isomer of PDMP, inhibits the growth of cultured rabbit skin fibroblasts and serves as an effective inhibitor of UDP-glucose:ceramide glucosyltransferase.

Isoastilbin is a dihydroflavonol glycoside compound found in Rhizoma Smilacis glabrae and Astragalus membranaceus. Isoastilbin inhibits glucosyltransferase (GTase) with an IC50 value of 54.3 μg/mL and possesses anti-acne and tyrosinase inhibition properties. Additionally, isoastilbin demonstrates neuroprotective, antioxidation, antimicrobial, and anti-apoptotic properties, indicating potential for Alzheimer's disease research.

Macrocarpal H has anti-glucosyltransferase, and anti-bacterial activities.

Macrocarpal I has anti-glucosyltransferase, and anti-bacterial activities.

Macrocarpal J has anti-bacterial activity, it also has anti-glucosyltransferase activity.

Miglustat hydrochloride (N-Butyldeoxynojirimycin hydrochloride) is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease.

beta-1,4-Glucuronyltransferase 1 is a glucosyltransferase enzyme. It facilitates the transfer of glucuronic acid to both the alpha and beta isomers of xylose.